Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more

Conditions: Chronic Hepatitis B
Interventions: Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: HCV
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 19 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Hepatitis B, Chronic
Interventions: HepTcell, Placebo; Biological · Drug
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Garden Grove, California • Redwood City, California • San Jose, California + 2 more

Conditions: Chronic Hepatitis C
Interventions: Pioglitazone (Actos); Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C Virus Infection
Interventions: Daclatasvir, Asunaprevir, Pegylated interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 20
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 17 more

Conditions: Hepatitis D, Chronic
Interventions: JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Redwood City, California • Boston, Massachusetts

Conditions: Hepatitis C, Chronic, Substance Use Disorders
Interventions: Peer specialist (PS), Incentives, telehealth visits, phone access; Behavioral
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Interventions: No interventions; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 8
States / cities: Palo Alto, California • Indianapolis, Indiana • St Louis, Missouri + 5 more

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 47
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more

Conditions: Hepatitis C, Chronic
Interventions: Miravirsen, Telaprevir, Ribavirin; Drug
Lead sponsor: Santaris Pharma A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Chronic Hepatitis C Virus Infection
Interventions: CTS-1027, Placebo; Drug · Other
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 15 more

Conditions: Chronic Hepatitis B
Interventions: Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Interventions: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123); Device
Lead sponsor: HepQuant, LLC; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatitis C
Interventions: PF-00868554, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Orlando, Florida + 5 more

Conditions: End Stage Renal Disease, Hepatitis C Infection
Interventions: Affinity plasmapheresis; Device
Lead sponsor: Aethlon Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C
Interventions: TMC435, Placebo, Peg-IFN-alfa-2a (P), Ribavirin (R); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more

Conditions: Chronic Hepatitis B
Interventions: TAF, TDF, TAF Placebo, TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Pasadena, California + 11 more

Conditions: CHRONIC HEPATITIS B
Interventions: CTH Chronic Hepatitis B; Drug
Lead sponsor: Nguyen Thi Trieu, MD; Individual
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Chronic Hepatitis C Virus Genotype 1
Interventions: BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Chronic HCV Infection
Interventions: LDV/SOF, SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 9 more

Conditions: Hepatitis C, Chronic, Hepatitis C
Interventions: GSK625433/placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Chronic Hepatitis B
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Foster City, California

Conditions: Hepatitis C
Interventions: fluvastatin; Drug
Lead sponsor: Bader, Ted, M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Linkage to Care for Persons With Hep C Infection

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Study of CTS-1027 in Hepatitis C Patients

Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment

Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Safety Study of the Aethlon Hemopurifier

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults

Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.

Fluvastatin Versus Hepatitis C Virus